Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Antibe Therapeutics Announces Intent to Unify Intellectual..

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Dec 18, 2020 9:45am

92 Views

Post# 32139070

RE:RE:Antibe Therapeutics Announces Intent to Unify Intellectual..

It sounds more like a deparate attempt on you clubhouse to get last chance at some cheapies............ mgmt is unturing all rocks to maximize value and overall $$$$ value...................

clubhouse19 wrote: Looks like they may be getting desperate and trying to make the company more attractive with fluff.

Mole101 wrote:
Antibe Therapeutics Announces Intent to Unify Intellectual Property Ownership

Supports U.S. capital markets strategy, large market partnering and pipeline expansion initiatives -

Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF) (the "Company"), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has commenced preliminary discussions to amalgamate Antibe Holdings Inc. ("Holdings") with the Company in order to unify the intellectual property ("IP") ownership of the Company’s drugs and platform. The Company believes that such an initiative would unlock value for potential partners and investors while simplifying IP protection for pipeline expansion efforts now underway.

"As described in our ongoing disclosures, the Company was founded with an exclusive license from Holdings," commented Dan Legault, Antibe’s CEO. "Based on this IP, we have achieved human proof-of-concept for otenaproxesul and developed compelling preclinical data for our other pipeline drugs. As we map out strategic initiatives with prospective partners and healthcare-specialized investors, we expect full ownership of the underlying IP to strengthen our corporate position. It also represents another step in our growth strategy, complementing our recent graduation to the TSX, share consolidation and the appointment of U.S.-based directors."
The Company will update the market upon further material developments as they are achieved.